Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

Sadahisa Ogasawara,Hiroaki Kanzaki,Keisuke Koroki,Kengo Kanayama,Susumu Maruta,Kazufumi Kobayashi,Souichiro Kiyono,Masato Nakamura,Naoya Kanogawa,Takayuki Kondo,Eiichiro Suzuki,Yoshihiko Ooka,Shingo Nakamoto,Akinobu Tawada,Tetsuhiro Chiba,Makoto Arai,Hiroyuki Nakada,Nobuko Yamaguchi,Hideki Hanaoka,Naoya Kato

Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

2020

TPS595Background: CYT001 (CYTLIMIC Inc.) is a novel cancer vaccine involving artificial intelligence (AI)-designed shared-antigen peptides and optimal combined adjuvants that boost the cancer-immun...

Keywords:

Hepatocellular carcinoma
CTL*
Cancer vaccine
Cancer research
Medicine
Antigen
Pathology
in patient
antigen specific
Artificial intelligence
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations